About the Authors
- Verena Rombach-Riegraf
-
Contributed equally to this work with: Verena Rombach-Riegraf, Anette C. Karle, Babette Wolf
* E-mail: verena.rombach-riegraf@novartis.com (VR-R); anette.karle@novartis.com (ACK); andrea.kiessling@novartis.com (AK)
Affiliation Novartis Pharma AG, Technical R&D, Biologics Process R&D, Late Phase Analytical & Pharmaceutical Development, Werk Klybeck, Basel, Switzerland
- Anette C. Karle
-
Contributed equally to this work with: Verena Rombach-Riegraf, Anette C. Karle, Babette Wolf
* E-mail: verena.rombach-riegraf@novartis.com (VR-R); anette.karle@novartis.com (ACK); andrea.kiessling@novartis.com (AK)
Affiliation Novartis Pharma AG, Integrated Biologics Profiling Unit, Immunogenicity Risk Assessment, Werk Klybeck, Basel, Switzerland
- Babette Wolf
-
Contributed equally to this work with: Verena Rombach-Riegraf, Anette C. Karle, Babette Wolf
Affiliation Novartis Pharma AG, Pre-clinical Safety, Biologics Safety and Disposition, Experimental Pathology, Immunosafety, Werk Klybeck, Basel, Switzerland
- Laetitia Sordé
-
Affiliation Novartis Pharma AG, Integrated Biologics Profiling Unit, Immunogenicity Risk Assessment, Werk Klybeck, Basel, Switzerland
- Stephan Koepke
-
Affiliation Novartis Pharma AG, Integrated Biologics Profiling Unit, Immunogenicity Risk Assessment, Werk Klybeck, Basel, Switzerland
- Sascha Gottlieb
-
Affiliation Novartis Pharma AG, Integrated Biologics Profiling Unit, Immunogenicity Risk Assessment, Werk Klybeck, Basel, Switzerland
- Jennifer Krieg
-
Current address: Molecular Partners AG, Schlieren-Zürich, Switzerland,
Affiliation Novartis Pharma AG, Pre-clinical Safety, Biologics Safety and Disposition, Experimental Pathology, Immunosafety, Werk Klybeck, Basel, Switzerland
- Marie-Claude Djidja
-
Affiliation Novartis Pharma AG, Technical R&D, Biologics Process R&D, Late Phase Analytical & Pharmaceutical Development, Werk Klybeck, Basel, Switzerland
- Aida Baban
-
Current address: Novartis Pharma AG, Global Standards Governance Office, Basel, Switzerland
Affiliation Novartis Pharma AG, Pre-clinical Safety Biologics Safety and Disposition, Bioanalytics, Werk Klybeck, Basel, Switzerland
- Sebastian Spindeldreher
-
Affiliation Novartis Pharma AG, Pre-clinical Safety Biologics Safety and Disposition, Bioanalytics, Werk Klybeck, Basel, Switzerland
- Atanas V. Koulov
-
Current address: F. Hoffmann-La Roche AG, Pharma Technical Development Europe (Biologics) Analytics, Basel, Switzerland,
Affiliation Novartis Pharma AG, Technical R&D, Biologics Process R&D, Late Phase Analytical & Pharmaceutical Development, Werk Klybeck, Basel, Switzerland
- Andrea Kiessling
-
* E-mail: verena.rombach-riegraf@novartis.com (VR-R); anette.karle@novartis.com (ACK); andrea.kiessling@novartis.com (AK)
Affiliation Novartis Pharma AG, Pre-clinical Safety, Biologics Safety and Disposition, Experimental Pathology, Immunosafety, Werk Klybeck, Basel, Switzerland
Competing Interests
The authors have declared that no competing interests exist.
Author Contributions
Conceived and designed the experiments: VR-R ACK BW AVK AK. Performed the experiments: VR-R BW LS SK SG JK M-CD AB. Analyzed the data: VR-R ACK BW LS SK SG M-CD AB SS AVK AK. Wrote the paper: VR-R ACK BW LS M-CD SS AVK AK.